1.27
4.96%
+0.06
After Hours:
1.2691
-0.0009
-0.07%
Veru Inc stock is currently priced at $1.27, with a 24-hour trading volume of 1.28M.
It has seen a +4.96% increased in the last 24 hours and a +108.23% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.26 pivot point. If it approaches the $1.30 resistance level, significant changes may occur.
Previous Close:
$1.21
Open:
$1.24
24h Volume:
1.28M
Market Cap:
$185.90M
Revenue:
$15.93M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.9203
EPS:
-1.38
Net Cash Flow:
$-59.50M
1W Performance:
-3.05%
1M Performance:
+108.23%
6M Performance:
+39.56%
1Y Performance:
-0.78%
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
305-509-6897
Address
4400 Biscayne Boulevard, Suite 888, Miami, FL
Veru Inc Stock (VERU) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-13-21 | Initiated | Jefferies | Buy |
Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
Mar-20-19 | Initiated | Oppenheimer | Outperform |
Jul-03-18 | Initiated | Maxim Group | Buy |
Veru Inc Stock (VERU) Latest News
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
GlobeNewswire Inc.
What Makes Veru (VERU) a New Buy Stock
Zacks Investment Research
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Veru Reschedules Annual Meeting of Shareholders
GlobeNewswire Inc.
Veru Inc Stock (VERU) Financials Data
Veru Inc (VERU) Revenue 2024
VERU reported a revenue (TTM) of $15.93 million for the quarter ending December 31, 2023, a -42.55% decline year-over-year.
Veru Inc (VERU) Net Income 2024
VERU net income (TTM) was -$64.59 million for the quarter ending December 31, 2023, a +44.50% increase year-over-year.
Veru Inc (VERU) Cash Flow 2024
VERU recorded a free cash flow (TTM) of -$59.50 million for the quarter ending December 31, 2023, a +19.70% increase year-over-year.
Veru Inc (VERU) Earnings per Share 2024
VERU earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a +48.28% growth year-over-year.
About Veru Inc
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Cap:
|
Volume (24h):